A study demonstrates lipid nanoparticle vaccines that delay STING activation to preserve antigen expression and boost localized antitumor immunity.
Key Takeaways
- DMXAA release is controlled by a biodegradable linker
- Intratumoral or subcutaneous LNPs are preferentially internalized by myeloid cells
- Syn-STING vaccine elicits robust adaptive responses and Th1-biased T cell immunity